Amgen AMGN delivered yet another strong quarterly performance. Its second-quarter 2025 earnings and sales beat estimates. The ...

Amgen prevented Regeneron from competing on a level playing field and unfairly denied patients access to Praluent. This anticompetitive practice shut out an innovative therapy from the PCSK9 ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Amgen is taking the risky step of preparing to launch a biosimilar version of Regeneron’s blockbuster Eylea drug after winning a victory in an ongoing legal battle. The U.S. Court of Appeals for ...

Amgen sued Sanofi and Regeneron in 2014. Both drugs use lab-made antibodies to block PCSK9 proteins that inhibit removal of bad LDL cholesterol from the blood, but they achieve that result through ...

Analysts estimate that Amgen will report an earnings per share (EPS) of $5.26. The announcement from Amgen is eagerly anticipated, with investors seeking news of surpassing estimates and favorable ...

Strand Therapeutics announced on Thursday that it landed a $153 million Series B funding led by Kinnevik. The company’s ...